HK1056691A1 - Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia - Google Patents

Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Info

Publication number
HK1056691A1
HK1056691A1 HK03109170A HK03109170A HK1056691A1 HK 1056691 A1 HK1056691 A1 HK 1056691A1 HK 03109170 A HK03109170 A HK 03109170A HK 03109170 A HK03109170 A HK 03109170A HK 1056691 A1 HK1056691 A1 HK 1056691A1
Authority
HK
Hong Kong
Prior art keywords
rosuvastatin
treatment
familial hypercholesterolemia
heterozygous familial
heterozygous
Prior art date
Application number
HK03109170A
Other languages
English (en)
Inventor
Raza Ali
Hutchinson Howard Gerard
Original Assignee
Strazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1056691(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Strazeneca Ab filed Critical Strazeneca Ab
Publication of HK1056691A1 publication Critical patent/HK1056691A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK03109170A 2000-11-22 2003-12-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia HK1056691A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy
PCT/GB2001/005041 WO2002041895A1 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Publications (1)

Publication Number Publication Date
HK1056691A1 true HK1056691A1 (en) 2004-02-27

Family

ID=9903629

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03109170A HK1056691A1 (en) 2000-11-22 2003-12-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Country Status (35)

Country Link
US (1) US6858618B2 (pt)
EP (1) EP1339409B1 (pt)
JP (2) JP5062940B2 (pt)
KR (1) KR100815042B1 (pt)
CN (1) CN1268339C (pt)
AR (1) AR031766A1 (pt)
AT (1) ATE394103T1 (pt)
AU (2) AU2002214165B9 (pt)
BG (1) BG66009B1 (pt)
BR (1) BR0115511A (pt)
CA (1) CA2429263C (pt)
CY (1) CY1110428T1 (pt)
CZ (1) CZ301583B6 (pt)
DE (1) DE60133921D1 (pt)
DK (1) DK1339409T3 (pt)
EE (1) EE05507B1 (pt)
ES (1) ES2305118T3 (pt)
GB (1) GB0028429D0 (pt)
HK (1) HK1056691A1 (pt)
HU (1) HUP0301380A3 (pt)
IL (2) IL155919A0 (pt)
IS (1) IS6819A (pt)
MX (1) MXPA03004336A (pt)
MY (1) MY134902A (pt)
NO (1) NO326245B1 (pt)
NZ (1) NZ525754A (pt)
PL (1) PL365386A1 (pt)
PT (1) PT1339409E (pt)
RU (1) RU2294744C2 (pt)
SI (1) SI1339409T1 (pt)
SK (1) SK6212003A3 (pt)
TW (1) TWI238720B (pt)
UA (1) UA75614C2 (pt)
WO (1) WO2002041895A1 (pt)
ZA (1) ZA200303636B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
EA200501676A1 (ru) * 2003-04-25 2006-04-28 Джилид Сайэнс, Инк. Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
ATE490788T1 (de) * 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2005023778A2 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
US7244844B2 (en) * 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
AU2005247160A1 (en) * 2004-05-26 2005-12-08 Kgk Synergize Inc Functional foods comprising flavonoids and tocotrienols and methods thereof
CA2573857A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
KR100945763B1 (ko) 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 제조 방법
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
TW200800917A (en) * 2005-08-16 2008-01-01 Teva Pharma Crystalline rosuvastatin intermediate
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
CA2725052C (en) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates
AU2009268681B2 (en) 2008-07-08 2014-10-02 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
EP3689853B1 (en) 2012-09-17 2021-11-24 Madrigal Pharmaceuticals, Inc. Method of synthesizing thyroid hormone analogs and polymorphs thereof
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
EP3960740B1 (en) 2017-08-01 2023-11-15 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections
EA202193139A1 (ru) 2019-05-27 2022-03-01 Имматикс Юс, Инк. Вирусные векторы и их применение в адоптивной клеточной терапии
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
AU2022213405A1 (en) * 2021-02-01 2023-08-03 Madrigal Pharmaceuticals, Inc. Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate

Also Published As

Publication number Publication date
JP2010031047A (ja) 2010-02-12
PL365386A1 (en) 2005-01-10
BG66009B1 (bg) 2010-10-29
IL155919A (en) 2009-09-01
AR031766A1 (es) 2003-10-01
CA2429263C (en) 2009-03-17
DK1339409T3 (da) 2008-09-08
AU1416502A (en) 2002-06-03
HUP0301380A3 (en) 2007-03-28
MXPA03004336A (es) 2003-08-19
AU2002214165B9 (en) 2013-07-04
PT1339409E (pt) 2008-07-07
CN1268339C (zh) 2006-08-09
DE60133921D1 (de) 2008-06-19
BG107811A (bg) 2004-03-31
JP2004522714A (ja) 2004-07-29
CZ301583B6 (cs) 2010-04-21
EE200300239A (et) 2003-08-15
KR100815042B1 (ko) 2008-03-18
ES2305118T3 (es) 2008-11-01
ATE394103T1 (de) 2008-05-15
IL155919A0 (en) 2003-12-23
RU2294744C2 (ru) 2007-03-10
HUP0301380A2 (hu) 2003-10-28
CN1630520A (zh) 2005-06-22
NO20032292D0 (no) 2003-05-21
TWI238720B (en) 2005-09-01
US6858618B2 (en) 2005-02-22
MY134902A (en) 2007-12-31
CY1110428T1 (el) 2015-04-29
EP1339409A1 (en) 2003-09-03
NO20032292L (no) 2003-07-17
JP5062940B2 (ja) 2012-10-31
SK6212003A3 (en) 2003-11-04
US20040072852A1 (en) 2004-04-15
UA75614C2 (uk) 2006-05-15
BR0115511A (pt) 2003-12-30
NZ525754A (en) 2004-10-29
AU2002214165B2 (en) 2006-12-14
GB0028429D0 (en) 2001-01-10
WO2002041895A1 (en) 2002-05-30
IS6819A (is) 2003-05-19
EE05507B1 (et) 2012-02-15
NO326245B1 (no) 2008-10-27
KR20030048479A (ko) 2003-06-19
EP1339409B1 (en) 2008-05-07
ZA200303636B (en) 2004-08-12
CZ20031406A3 (cs) 2003-09-17
CA2429263A1 (en) 2002-05-30
SI1339409T1 (sl) 2008-08-31

Similar Documents

Publication Publication Date Title
AU1416502A (en) Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
GB9912411D0 (en) Compounds useful in therapy
GB9912413D0 (en) Compounds useful in therapy
IL139899A (en) Uracil compounds and use thereof
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
GB9912410D0 (en) Compounds useful in therapy
GB0105613D0 (en) Pharmaceutically effective compounds and their use
HUP0401913A3 (en) Medicine for preventing and treating bromhidrosis
GB9912416D0 (en) Compounds useful in therapy
GB9912415D0 (en) Compounds useful in therapy
GB0112237D0 (en) Compounds and their therapeutic use
GB0112236D0 (en) Compounds and their therapeutic use
AU2002364385A1 (en) Implantable device and the use thereof
GB0130736D0 (en) Compounds and their therapeutic use
GB0112689D0 (en) Dispenser and treatment means
AU2002357468A1 (en) Use of 2-acylindoles in the treatment of tumors
GB9909843D0 (en) Compounds and their use
AU145797S (en) Medical dressing
GB0018888D0 (en) Compounds and their therapeutic use
AU2002256588A1 (en) Catalase-inactivating compounds and the use thereof
GB9904691D0 (en) Compounds useful in therapy
GB9910772D0 (en) Compounds useful in therapy
GB9910769D0 (en) Compounds useful in therapy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171116